Cantor Fitzgerald lowered the firm’s price target on Apellis (APLS) to $35 from $39 and keeps an Overweight rating on the shares following the Q4 pre-announcement. The C3G launch is going well, but the lack of formal guidance is likely weighing on the shares, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals: Syfovre and Empaveli Outperformance Plus Pipeline Upside Support Undervalued Buy Rating and $45 Target
- Apellis Pharmaceuticals: Durable Growth Outlook and Multiple 2025–2026 Catalysts Support Buy Rating
- Apellis Pharmaceuticals: Empaveli Momentum, Syfovre Franchise Durability, and Multi-Indication Expansion Support Reiterated Buy and $45 Target
- Apellis falls -17.3%
- Apellis reports preliminary FY25 U.S. net product revenues of $689M